AXILIEVA (Axitinib Tablets 5mg) is a potent oral targeted anticancer medication manufactured by Allieva Pharma Private Limited, formulated specifically for inhibiting tumor growth by selectively blocking vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). It is primarily used for treating advanced renal cell carcinoma (RCC) especially after the failure of prior systemic therapy and certain other solid tumors in clinical or off-label use. The active ingredient Axitinib acts as a tyrosine kinase inhibitor (TKI) to disrupt angiogenesis, thereby restricting nutrient supply to tumors. Offered in 5 mg tablet form, conveniently packed in bottles containing 28 tablets, AXILIEVA requires prescription use and should be administered under strict medical supervision. The standard recommended dosage is 5 mg taken orally twice daily, which can be adjusted for patients with hepatic impairments or for better tolerance. Clinically observed side effects include hypertension, fatigue, diarrhea, appetite loss, nausea, vomiting, and hand–foot syndrome, with serious adverse events such as severe bleeding and gastrointestinal perforation being rare but notable. AXILIEVA ensures quality and efficacy with its genuine Indian manufacturing and is ideal for oncologists and hospitals seeking a reliable anti-cancer treatment option.

*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.